Skip to main content
. Author manuscript; available in PMC: 2010 Nov 29.
Published in final edited form as: Transplantation. 2004 Oct 15;78(7):966–971. doi: 10.1097/01.tp.0000142674.78268.01

TABLE 3.

Incidence and extent of weaning

Immunosuppression dosing regimen Alemtuzumab pretreated
Conventional immunosuppression
HCV+ HCV HCV+ HCV
Total alive/entered 27/38 (71.5%) 37/38 (97%) 17/26 (65%) 50/58 (86%)
Daily multidrug therapy 2 3 6 17
Daily monotherapy 6 10 10 32
Every other day 10 8 1 0
3/wk 3 7 0 1
2/wk 4 4 0 0
1/wk 0 0
Every 2 weeks 1 2 0 0
Off immunosuppression 1 3 0 0